{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:32:59Z","timestamp":1793395979175,"version":"4.5.0"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110483","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:35:52Z","timestamp":1788849352000},"page":"110483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Computational small molecule drug discovery for multidrug-resistant tuberculosis: emerging targets and recent medicinal chemistry advances"],"prefix":"10.1016","volume":"182","author":[{"given":"Pardeep","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Bhima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai srujan kumar","family":"gadiparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Singampalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110483_bb0005","first-page":"18","article-title":"Munich personal RePEc archive tuberculosis is a fatal disease among some developing countries of the world","volume":"3","author":"Mohajan","year":"2015","journal-title":"Am. J. Infect. Dis. Microbiol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0010","doi-asserted-by":"crossref","unstructured":"K. Dheda, F. Mirzayev, D.M. Cirillo, Z. Udwadia, K.E. Dooley, K.-C. Chang, S.V. Omar, A. Reuter, T. Perumal, C.R. Horsburgh Jr, Others, Multidrug-resistant tuberculosis, Nat. Rev. Dis. Primers 10 (2024) 22.","DOI":"10.1038\/s41572-024-00504-2"},{"key":"10.1016\/j.bioorg.2026.110483_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116785","article-title":"Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment","volume":"277","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0025","unstructured":"World Health Organization, Global TB Rep., 2025. Doi: 978%2092%204%20156450%202."},{"key":"10.1016\/j.bioorg.2026.110483_bb0030","doi-asserted-by":"crossref","unstructured":"K.A. Abrahams, S.M. Batt, S.S. Gurcha, N. Veerapen, G. Bashiri, G.S. Besra, DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid, Nat. Commun. 14 (2023) 1\u201310. Doi: https:\/\/doi.org\/10.1038\/s41467-023-39300-z.","DOI":"10.1038\/s41467-023-39300-z"},{"key":"10.1016\/j.bioorg.2026.110483_bb0035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.drudis.2020.02.003","article-title":"The quest for the holy grail: new antitubercular chemical entities, targets and strategies","volume":"25","author":"Husz\u00e1r","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.110483_bb0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1039\/D3MD00019B","article-title":"Recent developments of imidazo[1,2-a]pyridine analogues as antituberculosis agents","volume":"14","author":"Samanta","year":"2023","journal-title":"RSC Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.110483_bb0045","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.accounts.0c00878","article-title":"Strategies to combat multi-drug resistance in tuberculosis","volume":"54","author":"Singh","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110483_bb0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","article-title":"Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria","volume":"19","author":"Piddock","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bioorg.2026.110483_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.00749-08","article-title":"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development","volume":"53","author":"van den Boogaard","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110483_bb0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMp068273","article-title":"XDR tuberculosis\u2014implications for global public health","volume":"356","author":"Raviglione","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110483_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jgg.2016.10.002","article-title":"Others, drug resistance mechanisms and novel drug targets for tuberculosis therapy","volume":"44","author":"Islam","year":"2017","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.bioorg.2026.110483_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.02452","article-title":"Repurposing and revival of the drugs: a new approach to combat the drug resistant tuberculosis","volume":"8","author":"Sharma","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0075","first-page":"1413","article-title":"Drug repositioning in the treatment of malaria and TB, future","volume":"3","author":"Nzila","year":"2011","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.rppnen.2017.10.009","article-title":"New drugs and perspectives for new anti-tuberculosis regimens","volume":"24","author":"Tiberi","year":"2018","journal-title":"Pulmonology"},{"key":"10.1016\/j.bioorg.2026.110483_bb0085","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccm.2019.08.001","article-title":"New drugs for the treatment of tuberculosis","volume":"40","author":"Ignatius","year":"2019","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.bioorg.2026.110483_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijid.2014.12.031","article-title":"Repurposing\u2014a ray of hope in tackling extensively drug resistance in tuberculosis","volume":"32","author":"Maitra","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0100","first-page":"1","article-title":"HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis","volume":"21","author":"Sultana","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.bioorg.2026.110483_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.15","article-title":"Tuberculosis\u2014drugs in the 2016 development pipeline","volume":"3","author":"Laughon","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.bioorg.2026.110483_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/EBC20160063","article-title":"Intrinsic, adaptive and acquired antimicrobial resistance in gram-negative bacteria","volume":"61","author":"Arzanlou","year":"2017","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0125","article-title":"New anti-tuberculosis drugs and regimens: 2015 update","volume":"1","author":"D\u2019Ambrosio","year":"2015","journal-title":"ERJ Open Research"},{"key":"10.1016\/j.bioorg.2026.110483_bb0130","series-title":"Molecular Genetics of Mycobacteria","first-page":"411","article-title":"Molecular basis of drug resistance in Mycobacterium tuberculosis","author":"Cohen","year":"2014"},{"key":"10.1016\/j.bioorg.2026.110483_bb0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/antibiotics3030317","article-title":"Drug resistance mechanisms in Mycobacterium tuberculosis","volume":"3","author":"Palomino","year":"2014","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioorg.2026.110483_bb0140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2015.01.014","article-title":"The complex evolution of antibiotic resistance in Mycobacterium tuberculosis","volume":"32","author":"Fonseca","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0145","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1124410","article-title":"The competitive cost of antibiotic resistance in Mycobacterium tuberculosis","volume":"312","author":"Gagneux","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110483_bb0150","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2878","article-title":"Others, evolution and transmission of drug-resistant tuberculosis in a Russian population","volume":"46","author":"Casali","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bioorg.2026.110483_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0160","doi-asserted-by":"crossref","unstructured":"St. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V Gordon, K. Eiglmeier, S. Gas, C.E. Barry Iii, others, Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature 396 (1998) 190.","DOI":"10.1038\/24206"},{"key":"10.1016\/j.bioorg.2026.110483_bb0165","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09657","article-title":"The challenge of new drug discovery for tuberculosis","volume":"469","author":"Koul","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110483_bb0170","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.bmc.2014.12.031","article-title":"Perspective: challenges and opportunities in TB drug discovery from phenotypic screening","volume":"23","author":"Manjunatha","year":"2015","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.110483_bb0175","doi-asserted-by":"crossref","unstructured":"S.T. Cole, B. R, P. J, G. T, C. C, H. D, G.S. V, E. K, G. S, B. CE, T. F, B. K, B. D, B. D, C. T, C. R, D. R, D. K, F. T, G. S, H. N, H. S, H. T, B.B. Jagels, Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature 393 (1998) 537\u2013544.","DOI":"10.1038\/31159"},{"key":"10.1016\/j.bioorg.2026.110483_bb0180","series-title":"encyclopedia of Parasitology","first-page":"1","article-title":"Drug targets","author":"Mehlhorn","year":"2015"},{"key":"10.1016\/j.bioorg.2026.110483_bb0185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/AAC.05270-11","article-title":"MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212","volume":"56","author":"La Rosa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110483_bb0190","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.3390\/app10124248","article-title":"Structure-based drug design for tuberculosis: challenges still ahead","volume":"10","author":"Bruch","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.bioorg.2026.110483_bb0195","doi-asserted-by":"crossref","first-page":"13259","DOI":"10.3390\/ijms222413259","article-title":"Drug discovery for Mycobacterium tuberculosis using structure-based computer-aided drug design approach","volume":"22","author":"Ejalonibu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110483_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/138955707779802633","article-title":"Cheminformatics in anti-infective agents discovery","volume":"7","author":"Sardari","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200214","article-title":"Drug re-engineering and repurposing: a significant and rapid approach to tuberculosis drug discovery","volume":"355","author":"Reddy","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0210","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/acs.jmedchem.0c00007","article-title":"Fragment-based design of mycobacterium tuberculosis inha inhibitors","volume":"63","author":"Sabbah","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2022.880432","article-title":"Structural characterization of Mycobacterium abscessus Phosphopantetheine adenylyl transferase ligand interactions: implications for fragment-based drug design","volume":"9","author":"Thomas","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2026.110483_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810669","article-title":"Fragment-based drug discovery against mycobacteria: the success and challenges","volume":"23","author":"Togre","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110483_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111415","article-title":"Implications of fragment-based drug discovery in tuberculosis and HIV","volume":"15","author":"Mallakuntla","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110483_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200214","article-title":"Drug re-engineering and repurposing: a significant and rapid approach to tuberculosis drug discovery","volume":"355","author":"Reddy","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0235","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cmi.2018.11.010","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis","volume":"25","author":"Lange","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.bioorg.2026.110483_bb0240","unstructured":"W.H. Organization, Others, WHO consolidated guidelines on drug-resistant tuberculosis treatment, World Health Organization, 2019."},{"key":"10.1016\/j.bioorg.2026.110483_bb0245","unstructured":"M. Frick, A. Gaudino, M. Harrington, T. Horn, R. Jefferys, J. Johnson, E. Lessem, M. Low, L. McKenna, Pipeline Report: HIV, TB \\& HCV Drugs, diagnostics, vaccines, preventive Technologies, cure research, and immune-based and gene therapies in development. 2017 [cited 2017 14th August], Treatment Action Group.(Accessed: March 2022) (2017)."},{"key":"10.1016\/j.bioorg.2026.110483_bb0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1574-6968.2006.00350.x","article-title":"Azole antifungals as novel chemotherapeutic agents against murine tuberculosis","volume":"261","author":"Ahmad","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb0255","doi-asserted-by":"crossref","unstructured":"S. De Lorenzo, J.W. Alffenaar, G. Sotgiu, R. Centis, L. D'Ambrosio, S. Tiberi, M.S. Bolhuis, R. van Altena, P. Viggiani, A. Piana, others, Efficacy and safety of meropenem--clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB, Eur. Respir. J. 41 (2013) 1386\u20131392.","DOI":"10.1183\/09031936.00124312"},{"key":"10.1016\/j.bioorg.2026.110483_bb0260","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/molecules25020415","article-title":"Identification and repurposing of trisubstituted harmine derivatives as novel inhibitors of Mycobacterium tuberculosis phosphoserine phosphatase","volume":"25","author":"Pierson","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110483_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics6010003","article-title":"Thioridazine: a non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of Mycobacterium tuberculosis due to its multi-mechanisms of action","volume":"6","author":"Amaral","year":"2017","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioorg.2026.110483_bb0270","series-title":"Ontological and Bioinformatic Analysis of Anti-Coronavirus Drugs and their Implication for Drug Repurposing against COVID-19","author":"Liu","year":"2020"},{"key":"10.1016\/j.bioorg.2026.110483_bb0275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijid.2014.12.031","article-title":"Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis","volume":"32","author":"Maitra","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0280","doi-asserted-by":"crossref","unstructured":"A. Maitra, D. Evangelopoulos, A. Chrzastek, L.T. Martin, A. Hanrath, E. Chapman, H.C. Hailes, M. Lipman, T.D. McHugh, S.J. Waddell, Others, Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis, J. Antimicrob. Chemother. 75 (2020) 3194\u20133201.","DOI":"10.1093\/jac\/dkaa307"},{"key":"10.1016\/j.bioorg.2026.110483_bb0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jgar.2022.09.001","article-title":"Pretomanid development and its clinical roles in treating tuberculosis","volume":"31","author":"Fekadu","year":"2022","journal-title":"Journal of Global Antimicrobial Resistance"},{"key":"10.1016\/j.bioorg.2026.110483_bb0290","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/pathogens11020128","article-title":"Pediatric tuberculosis research and development: progress, priorities and funding opportunities","volume":"11","author":"McKenna","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.bioorg.2026.110483_bb0295","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/jac\/dkz018","article-title":"Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria","volume":"74","author":"Das","year":"2019","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.bioorg.2026.110483_bb0300","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1021\/acs.jmedchem.7b01622","article-title":"Fragment-based approach to targeting Inosine-5\u2032-monophosphate dehydrogenase (IMPDH) from Mycobacterium tuberculosis","volume":"61","author":"Trapero","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0305","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1021\/acsomega.1c00369","article-title":"Synthesis and biological evaluation of novel Benzhydrylpiperazine-coupled Nitrobenzenesulfonamide hybrids","volume":"6","author":"Murthy","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110483_bb0310","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acsmedchemlett.9b00515","article-title":"Improving the potency of N -Aryl-2,5-dimethylpyrroles against multidrug-resistant and intracellular mycobacteria","volume":"11","author":"Touitou","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb0315","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/acsmedchemlett.1c00431","article-title":"Structural Rigidification of N -aryl-pyrroles into indoles active against intracellular and drug-resistant mycobacteria","volume":"13","author":"Semenya","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsinfecdis.0c00622","article-title":"Design and synthesis of Pyrano[3,2- b ]indolones showing Antimycobacterial activity","volume":"7","author":"Monakhova","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0325","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsinfecdis.0c00325","article-title":"A Coumarin-based analogue of Thiacetazone as dual covalent inhibitor and potential fluorescent label of HadA in Mycobacterium tuberculosis","volume":"7","author":"Farjallah","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0330","doi-asserted-by":"crossref","first-page":"13240","DOI":"10.1021\/acs.jmedchem.2c01064","article-title":"Structure-based optimization of Coumestan derivatives as polyketide synthase 13-Thioesterase(Pks13-TE) inhibitors with improved hERG profiles for Mycobacterium tuberculosis treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0335","doi-asserted-by":"crossref","first-page":"10534","DOI":"10.1021\/acs.jmedchem.2c00718","article-title":"Design, synthesis, and biological evaluation of Pyrrole-2-carboxamide derivatives as mycobacterial membrane protein large 3 inhibitors for treating drug-resistant tuberculosis","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0340","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/acs.jmedchem.1c01586","article-title":"Optimization of TAM16, a Benzofuran that inhibits the Thioesterase activity of Pks13; evaluation toward a preclinical candidate for a novel Antituberculosis clinical target","volume":"65","author":"Wilson","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0345","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acs.jmedchem.1c01565","article-title":"In vitro and in vivo inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl transferase PptT by Amidinoureas","volume":"65","author":"Ottavi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0350","doi-asserted-by":"crossref","unstructured":"M. Shyam, H. Verma, G. Bhattacharje, P. Mukherjee, S. Singh, S. Kamilya, P. Jalani, S. Das, A. Dasgupta, A. Mondal, A.K. Das, A. Singh, F. Brucoli, C. Bagn\u00e9ris, R. Dickman, V.N. Basavanakatti, P. Naresh Babu, V. Sankaran, A. Dev, B.N. Sinha, S. Bhakta, V. Jayaprakash, Mycobactin analogues with excellent pharmacokinetic profile demonstrate potent antitubercular specific activity and exceptional efflux pump inhibition, J. Med. Chem. 65 (2022) 234\u2013256. Doi: https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01349.","DOI":"10.1021\/acs.jmedchem.1c01349"},{"key":"10.1016\/j.bioorg.2026.110483_bb0355","doi-asserted-by":"crossref","first-page":"12790","DOI":"10.1021\/acs.jmedchem.1c00837","article-title":"1,3-Diarylpyrazolyl-acylsulfonamides as potent anti-tuberculosis agents targeting Cell Wall biosynthesis in Mycobacterium tuberculosis","volume":"64","author":"Khonde","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0360","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1021\/acs.jmedchem.1c00263","article-title":"Discovery of novel Thiophene-arylamide derivatives as DprE1 inhibitors with potent Antimycobacterial activities","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0365","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1021\/acs.jmedchem.0c02153","article-title":"Identification of novel tricyclic benzo[1,3]oxazinyloxazolidinones as potent antibacterial agents with excellent pharmacokinetic profiles against drug-resistant pathogens","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200459","article-title":"1 H -1,2,3-Triazole\u22124 H -chromene\u2212D-glucose hybrid compounds: synthesis and inhibitory activity against Mycobacterium tuberculosis protein tyrosine phosphatase B","volume":"356","author":"Thanh","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200444","article-title":"Synthesis, antimycobacterial, cytotoxicity, anti-inflammatory, in silico studies and molecular dynamics of pyrazole-embedded thiazolidin-4-one hybrids","volume":"356","author":"Kamat","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202203333","article-title":"Identification of 1,3-substituted pyrazole-based carboxamide derivatives as potent antitubercular agents","volume":"7","author":"Baliram Gaikwad","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110483_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2022.105370","article-title":"Discovery of potent antitubercular agents: design, synthesis and biological evaluation of 4-(3-(4-substitutedpiperazin-1-yl)-quinoxalin-2-yl)-naphthalen-1-ol analogues","volume":"82","author":"Nandikolla","year":"2022","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bioorg.2026.110483_bb0390","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cbdd.14060","article-title":"Synthesis, molecular docking, and biological evaluation of novel 1,2,4-triazole-isatin derivatives as potential Mycobacterium tuberculosis shikimate kinase inhibitors","volume":"100","author":"Dadlani","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.110483_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202200304","article-title":"Design, synthesis and biological evaluation of novel Spiro-[Chroman-2,4\u2032-Piperidin]-4-one analogs as anti-tubercular agents","volume":"19","author":"Chitti","year":"2022","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0400","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200545","article-title":"1,2,4-Triazole and benzimidazole fused dihydropyrimidine derivatives: design, green synthesis, antibacterial, antitubercular, and antimalarial activities","volume":"356","author":"Mokariya","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0405","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/jhet.4340","article-title":"Arylquinolinecarboxamides: synthesis, in vitro and in silico studies against Mycobacterium tuberculosis","volume":"58","author":"Bokosi","year":"2021","journal-title":"Journal of Heterocyclic Chem"},{"key":"10.1016\/j.bioorg.2026.110483_bb0410","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/acsomega.0c05690","article-title":"Design and synthesis of \u201cChloropicolinate amides and urea derivatives\u201d as novel inhibitors for Mycobacterium tuberculosis","volume":"6","author":"Konduri","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110483_bb0415","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000349","article-title":"Design, synthesis, in silico, and in vitro evaluation of 3-phenylpyrazole acetamide derivatives as antimycobacterial agents","volume":"354","author":"Gaikwad","year":"2021","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bioorg.2026.110483_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202200324","article-title":"Exploration of Isoxazole-carboxylic acid methyl Ester based 2-substituted Quinoline derivatives as promising Antitubercular agents","volume":"19","author":"Kumar Sahoo","year":"2022","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0425","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/cmdc.202000899","article-title":"Benzofuroxan derivatives as potent agents against multidrug-resistant Mycobacterium tuberculosis","volume":"16","author":"Fernandes","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110483_bb0430","doi-asserted-by":"crossref","first-page":"22385","DOI":"10.1039\/D2RA03318F","article-title":"Design, synthesis and biological evaluation of benzo-[ d ]-imidazo-[2,1- b ]-thiazole and imidazo-[2,1- b ]-thiazole carboxamide triazole derivatives as antimycobacterial agents","volume":"12","author":"Chitti","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110483_bb0435","article-title":"Design synthesis docking and biological study of pyrazole-35-diamine derivatives with potent antitubercular activity","volume":"6","author":"Pawar","year":"2022","journal-title":"Chem. Methodol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020155","article-title":"Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents","volume":"14","author":"Mori","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110483_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113580","article-title":"Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis","volume":"222","author":"Sahoo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0450","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1039\/D1MD00387A","article-title":"Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy","volume":"13","author":"Sahoo","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116777","article-title":"Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy","volume":"64","author":"Kumar Sahoo","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202204093","article-title":"Synthesis of novel 5-Oxo-1,2,4-Oxadiazole derivatives as Antitubercular agents and their molecular docking study toward Enoyl reductase (InhA) enzyme","volume":"8","author":"Reddy","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110483_bb0465","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s11030-022-10511-8","article-title":"Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies","volume":"27","author":"Modi","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0470","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/acs.jmedchem.2c01647","article-title":"Structure\u2013activity relationship of novel pyrimidine derivatives with potent inhibitory activities against Mycobacterium tuberculosis","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0475","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1021\/acsabm.2c00562","article-title":"Design and synthesis of Quinazolinone-Triazole hybrids as potent anti-tubercular agents","volume":"5","author":"Dutta","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.bioorg.2026.110483_bb0480","first-page":"927","article-title":"Design, synthesis, and biological activity profiling study of imidazolinone-based hydrazones as potential multitarget antimycobacterial agents","volume":"47","author":"Abdelhamed","year":"2024","journal-title":"Bull. Pharm. Sci. Assiut Univ."},{"key":"10.1016\/j.bioorg.2026.110483_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112075","article-title":"Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis","volume":"189","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000077","article-title":"Pyrazole\u2013coumarin and pyrazole\u2013quinoline chalcones as potential antitubercular agents","volume":"353","author":"Kumar","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0495","article-title":"New benzothiazinone linked 1, 2, 4-triazoles: design, synthesis, characterization, and evaluation of antitubercular activity","author":"Kannampally","year":"2020","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110483_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101301","article-title":"Isoniazid linked to sulfonate esters via hydrazone functionality: design, synthesis, and evaluation of antitubercular activity","volume":"15","author":"Ko\u00e7ak Aslan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110483_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27207130","article-title":"A hydrazine\u2013hydrazone adamantine compound shows antimycobacterial activity and is a probable inhibitor of MmpL3","volume":"27","author":"Briffotaux","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110483_bb0510","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3390\/ma15093085","article-title":"Differences in the structure and antimicrobial activity of Hydrazones derived from methyl 4-Phenylpicolinimidate","volume":"15","author":"Gobis","year":"2022","journal-title":"Materials"},{"key":"10.1016\/j.bioorg.2026.110483_bb0515","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1039\/D3MD00079F","article-title":"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant Staphylococcus aureus and Mycobacterium tuberculosis","volume":"14","author":"Ommi","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0520","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cbdd.13634","article-title":"Novel fatty acid-thiadiazole derivatives as potential antimycobacterial agents","volume":"95","author":"Mali","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.110483_bb0525","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/hc-2020-0109","article-title":"Design, synthesis and study of antibacterial and antitubercular activity of quinoline hydrazone hybrids","volume":"26","author":"G","year":"2020","journal-title":"Heterocycl. Commun."},{"key":"10.1016\/j.bioorg.2026.110483_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113668","article-title":"Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity","volume":"223","author":"Pfl\u00e9gr","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2019.01.073","article-title":"Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors","volume":"167","author":"Patel","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105133","article-title":"Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis","volume":"115","author":"Karunanidhi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103610","article-title":"Novel pyrazine based anti-tubercular agents: design, synthesis, biological evaluation and in silico studies","volume":"96","author":"Hassan","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0550","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bioorg.2019.01.054","article-title":"Design, synthesis and biological evaluation of (E)-5-styryl-1,2,4-oxadiazoles as anti-tubercular agents","volume":"86","author":"Atmaram Upare","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0555","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1021\/acsinfecdis.3c00341","article-title":"Discovery, synthesis, and optimization of 1,2,4-Triazolyl pyridines targeting Mycobacterium tuberculosis","volume":"9","author":"Berida","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110483_bb0560","doi-asserted-by":"crossref","first-page":"12272","DOI":"10.1039\/D0RA01348J","article-title":"Seeking potent anti-tubercular agents: design and synthesis of substituted- N -(6-(4-(pyrazine-2-carbonyl)piperazine\/homopiperazine-1-yl)pyridin-3-yl)benzamide derivatives as anti-tubercular agents","volume":"10","author":"Srinivasarao","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110483_bb0565","doi-asserted-by":"crossref","unstructured":"P.K. Deb, N.A. Al-Shar'i, K.N. Venugopala, M. Pillay, P. Borah, In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis, J. Enzyme Inhib. Med. Chem. 36 (2021) 869\u2013884. Doi: https:\/\/doi.org\/10.1080\/14756366.2021.1900162.","DOI":"10.1080\/14756366.2021.1900162"},{"key":"10.1016\/j.bioorg.2026.110483_bb0570","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s43094-020-00162-7","article-title":"Design and synthesis of new 3-((7-chloroquinolin-4-yl)amino)thiazolidin-4-one analogs as Mycobacterium tuberculosis DNA gyrase inhibitors","volume":"7","author":"Salve","year":"2021","journal-title":"Futur J Pharm Sci"},{"key":"10.1016\/j.bioorg.2026.110483_bb0575","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.13005\/ojc\/390610","article-title":"Discovery of new isoniazid derivatives as anti-tubercular agents: in silico studies, synthesis, and in vitro activity evaluation","volume":"39","author":"Mohd","year":"2023","journal-title":"Orient. J. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0580","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/molecules27092844","article-title":"Design, synthesis and biological evaluation of N-phenylindole derivatives as Pks13 inhibitors againstMycobacterium tuberculosis","volume":"27","author":"Cai","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110483_bb0585","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.4155\/fmc-2023-0066","article-title":"Design, synthesis and biological evaluation of novel Oxindole analogs as antitubercular agents","volume":"15","author":"Khetmalis","year":"2023","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0590","article-title":"Synthesis, biological evaluation and computational studies of new hydrazide derivatives containing 1,3,4-Oxadiazole as Antitubercular agents","volume":"23","author":"Zampieri","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.110483_bb0595","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2250575","article-title":"Discovery of pyrimidine-tethered benzothiazole derivatives as novel anti-tubercular agents towards multi- and extensively drug resistant Mycobacterium tuberculosis","volume":"38","author":"Hemeda","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104538","article-title":"Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents","volume":"107","author":"Dhameliya","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0605","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1039\/D3MD00115F","article-title":"Design, synthesis and biological evaluation of phenanthridine amide and 1,2,3-triazole analogues against Mycobacterium tuberculosis","volume":"14","author":"Nandikolla","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0610","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmc.2019.02.053","article-title":"Expansion of a novel lead targeting M. Tuberculosis DHFR as antitubercular agents","volume":"27","author":"Sharma","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0615","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1039\/D1MD00367D","article-title":"Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-a]pyridine analogues","volume":"13","author":"Khetmalis","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0620","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1039\/C9RA10663D","article-title":"Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents","volume":"10","author":"Alsayed","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110483_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2021.105137","article-title":"Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis","volume":"74","author":"Nandikolla","year":"2021","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bioorg.2026.110483_bb0630","doi-asserted-by":"crossref","unstructured":"H.S.P. Rao, R. Gunasundari, L.N. Adigopula, J. Muthukumaran, Design, synthesis, molecular docking and biological activity of pyrazolo[3,4-b]pyridines as promising lead candidates against Mycobacterium tuberculosis, (2023). Doi: https:\/\/doi.org\/10.1101\/2023.06.26.546517.","DOI":"10.1101\/2023.06.26.546517"},{"key":"10.1016\/j.bioorg.2026.110483_bb0635","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1007\/s11030-025-11152-3","article-title":"New pyrazole-based derivatives targeting MmpL3 transporter in Mycobacterium tuberculosis: design, synthesis, biological evaluation and molecular docking studies","volume":"29","author":"Maddipatla","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0640","article-title":"Design and evaluation of Quinoline-Schiff bases targeting Mtb DNA gyrase","volume":"22","author":"Shaik","year":"2025","journal-title":"In Vitro and Computational Approaches, Chemistry & Biodiversity"},{"key":"10.1016\/j.bioorg.2026.110483_bb0645","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.48047\/3w3ra843","article-title":"INSILICO screening of some chalcone isatin complex analogues against anti-tubercular potential","volume":"54","author":"Borra","year":"2025","journal-title":"CDF"},{"key":"10.1016\/j.bioorg.2026.110483_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130156","article-title":"Discovery of 1,3-Disubstituted Pyrazole derivatives as Mycobacterium tuberculosis inhibitors","volume":"121","author":"Wan","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2025.102628","article-title":"Integrative exploration of 2-phenylquinolin-4(1H)-one tethered 1,2,3-triazole derivatives: a comprehensive in vitro and in silico investigation towards novel anti-tubercular agents","volume":"152","author":"Mehavi","year":"2025","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bioorg.2026.110483_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139326","article-title":"Synthesis and computational studies of 1,3,4-thiadiazole and benzothiazole clubbed benzimidazole analogous as anti-tubercular and anti-protozoal agent","volume":"1319","author":"Patel","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110483_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42674","article-title":"Experimental and theoretical studies on antituberculosis activity of different benzimidazole derivatives","volume":"11","author":"K\u0131z\u0131ly\u0131ld\u0131r\u0131m","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2026.110483_bb0670","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2442703","article-title":"The new thiazolidine-2,4-dione-based hybrids with promising antimycobacterial activity: design, synthesis, biological evaluation, and drug interaction analysis","volume":"40","author":"Trotsko","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42593","article-title":"Generative AI, molecular docking and molecular dynamics simulations assisted identification of novel transcriptional repressor EthR inhibitors to target Mycobacterium tuberculosis","volume":"11","author":"Chikhale","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2026.110483_bb0680","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/life15020173","article-title":"Improved inhibitors targeting the thymidylate kinase of multidrug-resistant Mycobacterium tuberculosis with favorable pharmacokinetics","volume":"15","author":"Konate","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.bioorg.2026.110483_bb0685","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0043-1775424","article-title":"Synthesis, in vitro and in silico molecular docking studies of novel phthalimide\u2013pyrimidine hybrid analogues to thalidomide as potent antitubercular agents","volume":"09","author":"Shehta","year":"2025","journal-title":"SynOpen"},{"key":"10.1016\/j.bioorg.2026.110483_bb0690","article-title":"Design synthesis and biological evaluation of chromone fused 134-thiadiazoles as highly potent nontoxic inhibitors of enoyl-acyl carrier proteins in M. tuberculosis","author":"Kendre","year":"2024","journal-title":"IJNC"},{"key":"10.1016\/j.bioorg.2026.110483_bb0695","doi-asserted-by":"crossref","first-page":"86","DOI":"10.69857\/joapr.v13i1.722","article-title":"Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives","volume":"13","author":"Ramu","year":"2025","journal-title":"J. Appl. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110483_bb0700","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00044-025-03402-8","article-title":"6-Phenoxyl-4-aminoquinoline: synthesis and preliminary antitubercular-structure activity relationship analyses","volume":"34","author":"Beteck","year":"2025","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110483_bb0705","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1424017","article-title":"Identification of 2-(N-aryl-1,2,3-triazol-4-yl) quinoline derivatives as antitubercular agents endowed with InhA inhibitory activity","volume":"12","author":"Sabt","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0710","series-title":"Design and Synthesis of Pyridyl and 2-Hydroxyphenyl Chalcones with Antitubercular Activity","author":"Aziafor","year":"2024"},{"key":"10.1016\/j.bioorg.2026.110483_bb0715","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5530\/jyp.2024.16.93","article-title":"Innovative Thiophene Schiff bases: synthesis and evaluation as Antitubercular agents","volume":"16","author":"Paleti","year":"2024","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0720","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00044-024-03319-8","article-title":"Synthesis of 6-dialkylaminopyrimidine carboxamide analogues and their anti-tubercular properties","volume":"33","author":"Tshinavhe","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110483_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2024.101346","article-title":"Design, synthesis and docking studies of new molecular hybrids bearing benzimidazole and thiazolidine-2,4-dione as potential antitubercular agents","volume":"101","author":"Raghu","year":"2024","journal-title":"J. Indian Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110483_bb0730","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5530\/jyp.20251380","article-title":"Design, synthesis and evaluation of substituted Benzimidazoles as potent polyketide synthase 13 inhibitors for tuberculosis","volume":"17","author":"Krishnu","year":"2025","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0735","doi-asserted-by":"crossref","first-page":"14927","DOI":"10.1021\/acs.jmedchem.4c00441","article-title":"Design, synthesis, and evaluation of the antitubercular activity of 5-phenyl substituted-5, 6-dihydropyrido[2, 3- d ]pyrimidine-4, 7( 3H , 8H )-dione compounds","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0740","doi-asserted-by":"crossref","unstructured":"U.S.S. Kumbalathara A.D., P.C. Bartolomeu Halicki, K. Kalera, B.M. Swarts, K.H. Rohde, S.J. Sucheck, Synthesis and evaluation of Trehalose-Pks13 inhibitor conjugates targeting mycobacteria, Carbohydr. Res. 553 (2025) 109506. Doi: https:\/\/doi.org\/10.1016\/j.carres.2025.109506.","DOI":"10.1016\/j.carres.2025.109506"},{"key":"10.1016\/j.bioorg.2026.110483_bb0745","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/acs.jmedchem.5c01026","article-title":"Exploring indole-linked Triazole sulfonamide derivatives as potent mycobacterial carbonic anhydrase inhibitors: leveraging a tail approach for the design, synthesis, and in silico studiesan in-depth multidisciplinary study","volume":"68","author":"Singampalli","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep27792","article-title":"Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis","volume":"6","author":"Djaout","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110483_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0183060","article-title":"Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein","volume":"12","author":"Dharra","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.110483_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010154","article-title":"Naphthalimides selectively inhibit the activity of bacterial, replicative DNA ligases and display bactericidal effects against tubercle bacilli","volume":"22","author":"Korycka-Machala","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110483_bb0765","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jmgm.2015.05.001","article-title":"Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase","volume":"60","author":"Petersen","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2026.110483_bb0770","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14756366.2016.1190712","article-title":"Identification of Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) inhibitors among the derivatives of 5-phenylamino-2H-[1,2,4]triazin-3-one","volume":"31","author":"Gudzera","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0775","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2018.06.033","article-title":"Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents","volume":"155","author":"Chiarelli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0780","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejmech.2016.06.042","article-title":"Engineering another class of anti-tubercular lead: hit to lead optimization of an intriguing class of gyrase ATPase inhibitors","volume":"122","author":"Jeankumar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0785","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2014.12.046","article-title":"Design and development of novel Mycobacterium tuberculosis l-alanine dehydrogenase inhibitors","volume":"92","author":"Saxena","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0790","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2147\/DDDT.S97043","article-title":"Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosis L,D-transpeptidase 2","volume":"10","author":"Billones","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2026.110483_bb0795","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1016\/j.bmc.2016.07.051","article-title":"Design and development of new class of Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors","volume":"24","author":"Reshma","year":"2016","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.110483_bb0800","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.bbrc.2017.08.020","article-title":"Prioritization of natural compounds against mycobacterium tuberculosis 3-dehydroquinate dehydratase: a combined in-silico and in-vitro study","volume":"491","author":"Lone","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.110483_bb0805","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1128\/AEM.03916-15","article-title":"Discovery of novel haloalkane dehalogenase inhibitors","volume":"82","author":"Buryska","year":"2016","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0810","article-title":"Design, synthesis and antitubercular assessment of 1, 2, 3-triazole incorporated thiazolylcarboxylate derivatives","volume":"97","author":"Bakale","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb0815","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.1002\/slct.201902030","article-title":"Synthesis, anticancer and antimicrobial evaluation of new (E)-N\u2032-Benzylidene-2-(2-ethylpyridin-4-yl)-4-methylthiazole-5-carbohydrazides","volume":"4","author":"Muluk","year":"2019","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110483_bb0820","doi-asserted-by":"crossref","unstructured":"M. Imran, Abida, N.M. Alotaibi, H.K. Thabet, J.A. Alruwaili, S.M.B. Asdaq, L. Eltaib, M. Kamal, A.B.H. Alshammari, A.M.A. Alshammari, A. Alshehri, Computer-assisted discovery of safe and effective DprE1\/ aaRSs inhibitors against TB utilizing drug repurposing approach, J. Infect. Public Health 16 (2023) 554\u2013572. Doi: https:\/\/doi.org\/10.1016\/j.jiph.2023.02.005.","DOI":"10.1016\/j.jiph.2023.02.005"},{"key":"10.1016\/j.bioorg.2026.110483_bb0825","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bioorg.2018.12.018","article-title":"Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening","volume":"85","author":"Gao","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-20325-1","article-title":"Identification of hydantoin based Decaprenylphosphoryl-\u03b2-d-ribose oxidase (DprE1) inhibitors as antimycobacterial agents using computational tools","volume":"12","author":"Mali","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110483_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2026.130601","article-title":"Structure\u2013activity relationship\u2013driven lead optimization of pyrazole hydrazide\u2013hydrazone analogues as potent antimycobacterial agents: in vitro and in silico studies","volume":"136","author":"Kumar","year":"2026","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb0840","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202501301","article-title":"Exploration of pyridine-4-hydrazide derivatives as promising antitubercular agents: synthesis, biological evaluation, and in silico studies","volume":"10","author":"Kumar","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110483_bb0845","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70074","article-title":"Exploration of new dihydroindazole derivatives as promising anti-TB agents: design, synthesis, in silico, and biological evaluation","volume":"358","author":"Kumar","year":"2025","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb0850","first-page":"819","article-title":"Spirocyclic compounds: potential drug leads in the fight against Mycobacterium tuberculosis, future","volume":"17","author":"Kumar","year":"2025","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0855","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/jm501029r","article-title":"Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis","volume":"58","author":"\u0160ink","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0860","unstructured":"P.S. Shirude, P. Madhavapeddi, M. Naik, K. Murugan, V. Shinde, R. Nandishaiah, J. Bhat, A. Kumar, S. Hameed, G. Davies, H. Mcmiken, N. Hegde, A. Ambady, J. Venkatraman, M. Panda, B. Bandodkar, V.K. Sambandamurthy, J.A. Read, tuberculosis, (2013)."},{"key":"10.1016\/j.bioorg.2026.110483_bb0865","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ebiom.2016.05.006","article-title":"Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor","volume":"8","author":"Mart\u00ednez-Hoyos","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioorg.2026.110483_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094706","article-title":"Novel hybrid 1,2,4-and 1,2,3-triazoles targeting Mycobacterium tuberculosis enoyl acyl carrier protein reductase (InhA): design, synthesis, and molecular docking","volume":"23","author":"El Sawy","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110483_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112402","article-title":"Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors","volume":"199","author":"Do\u011fan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0880","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s11030-022-10511-8","article-title":"Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies","volume":"27","author":"Modi","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0885","doi-asserted-by":"crossref","first-page":"21820","DOI":"10.1021\/acsomega.2c01981","article-title":"Synthesis, molecular modeling study, and quantum-chemical-based investigations of Isoindoline-1,3-diones as Antimycobacterial agents","volume":"7","author":"Ahmad","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110483_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106125","article-title":"Novel diaryl ether derivatives as InhA inhibitors: design, synthesis and antimycobacterial activity","volume":"129","author":"Abdelaziz","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115744","article-title":"Inhibition of Mycobacterium tuberculosis InhA: design, synthesis and evaluation of new di-triclosan derivatives","volume":"28","author":"Armstrong","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0900","doi-asserted-by":"crossref","first-page":"30165","DOI":"10.1039\/D4RA05616G","article-title":"Benzenesulfonohydrazide-tethered non-fused and fused heterocycles as potential anti-mycobacterial agents targeting enoyl acyl carrier protein reductase (InhA) with antibiofilm activity","volume":"14","author":"Al-Warhi","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110483_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107138","article-title":"Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA)","volume":"144","author":"Khaleel","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127579","article-title":"Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents","volume":"30","author":"Phatak","year":"2020","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.110483_bb0915","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1080\/00397911.2019.1614630","article-title":"Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles","volume":"49","author":"Phatak","year":"2019","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2026.110483_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127579","article-title":"Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents","volume":"30","author":"Phatak","year":"2020","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.110483_bb0925","doi-asserted-by":"crossref","unstructured":"K.N. Venugopala, S. Chandrashekharappa, P.K. Deb, N.A. Al-Shar'i, M. Pillay, P. Tiwari, D. Chopra, P. Borah, R. Tamhaev, L. Mourey, C. Lherbet, B.E. Aldhubiab, C. Tratrat, M. Attimarad, A.B. Nair, N. Sreeharsha, R.P. Mailavaram, R. Venugopala, V. Mohanlall, M.A. Morsy, Identification of potent indolizine derivatives against mycobacterial tuberculosis: in vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies, Int. J. Biol. Macromol. 274 (2024). Doi: https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133285.","DOI":"10.1016\/j.ijbiomac.2024.133285"},{"key":"10.1016\/j.bioorg.2026.110483_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138415","article-title":"Synthesis, biological evaluation, and docking studies of pyrazole-linked benzothiazole hybrids as promising anti-TB agents","volume":"1311","author":"Mohamed-Ezzat","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110483_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133822","article-title":"Design and synthesis of novel benzimidazole linked thiazole derivatives as promising inhibitors of drug-resistant tuberculosis","volume":"1269","author":"Veena","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110483_bb0940","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1039\/D1ME00122A","article-title":"Molecular insights into Mmpl3 lead to the development of novel indole-2-carboxamides as antitubercular agents","volume":"7","author":"Ray","year":"2022","journal-title":"Molecular Systems Design and Engineering"},{"key":"10.1016\/j.bioorg.2026.110483_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115633","article-title":"Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: an effective strategy towards development of potent anti-tubercular agents","volume":"259","author":"Vasudevan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115351","article-title":"Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents","volume":"255","author":"Wen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0955","doi-asserted-by":"crossref","unstructured":"S.M. Bellapukonda, S. Singothu, A. Singampalli, R. Bandela, P. Kumar, V.M. Yaddanapudi, V. Bhandari, S. Nanduri, M. Enneiymy, M.F. AlAjm, A. oubella, Exploring spirocyclic isoquinoline-piperidine compounds in tuberculosis therapy: ADMET profiling, docking, DFT, MD simulations, and MMGBSA analysis, Comput. Biol. Chem. 118 (2025). Doi: https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108447.","DOI":"10.1016\/j.compbiolchem.2025.108447"},{"key":"10.1016\/j.bioorg.2026.110483_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2025.108954","article-title":"Computer-aided drug design approaches for the identification of potent inhibitors targeting elongation factor G of Mycobacterium tuberculosis","volume":"136","author":"Wani","year":"2025","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2026.110483_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.medntd.2025.100406","article-title":"Computational drug discovery of nitroimidazole compounds targeting Ddn protein of Mycobacterium tuberculosis: insights from QSAR modeling, ADMET, molecular docking, and molecular dynamics simulation studies","volume":"28","author":"Murugan","year":"2025","journal-title":"Medicine in Novel Technology and Devices"},{"key":"10.1016\/j.bioorg.2026.110483_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.insi.2025.100012","article-title":"Computational design, pharmacokinetics, molecular docking and molecular dynamic simulation of novel anti-tubercular inhibitors","volume":"1","author":"Nyijime","year":"2025","journal-title":"In Silico Research in Biomedicine"},{"key":"10.1016\/j.bioorg.2026.110483_bb0975","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11030-020-10107-0","article-title":"Structure-based drug design, synthesis and screening of MmaA1 inhibitors as novel anti-TB agents","volume":"25","author":"Veeravarapu","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110483_bb0980","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11224-019-01422-w","article-title":"Dual targeting approach for Mycobacterium tuberculosis drug discovery: insights from DFT calculations and molecular dynamics simulations","volume":"31","author":"Ejalonibu","year":"2020","journal-title":"Struct. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb0985","first-page":"443","article-title":"Structure-based design of Mycobacterium tuberculosis PptT-ACP complex inhibitors using derivative design and machine learning","author":"Alotaibi","year":"2025","journal-title":"Folia Microbiol."},{"key":"10.1016\/j.bioorg.2026.110483_bb0990","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s11756-025-01916-5","article-title":"Computational drug repurposing reveals potential alanine racemase inhibitors for combating drug-resistant tuberculosis","volume":"80","author":"LakshmanaPerumal","year":"2025","journal-title":"Biologia"},{"key":"10.1016\/j.bioorg.2026.110483_bb0995","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s11030-024-10946-1","article-title":"Suppressing Mycobacterium tuberculosis virulence and drug resistance by targeting Eis protein through computational drug discovery","volume":"29","author":"Kumar","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110483_bb1000","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1021\/jm401268f","article-title":"Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA gyrase B","volume":"56","author":"Kale","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1005","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bmcl.2013.12.080","article-title":"Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy","volume":"24","author":"Kale","year":"2014","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.110483_bb1010","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1021\/acs.jcim.1c01390","article-title":"Identification of potent DNA gyrase inhibitors active against Mycobacterium tuberculosis","volume":"62","author":"Pakamwong","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.110483_bb1015","doi-asserted-by":"crossref","first-page":"34462","DOI":"10.1039\/D1RA05630A","article-title":"Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies","volume":"11","author":"Mathpal","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110483_bb1020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acsmedchemlett.1c00549","article-title":"Structure-activity relationship of anti-Mycobacterium abscessus Piperidine-4-carboxamides, a new class of NBTI DNA gyrase inhibitors","volume":"13","author":"Beuchel","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110483_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110967","article-title":"Molecular mechanism of a triazole-containing inhibitor of Mycobacterium tuberculosis DNA gyrase","volume":"27","author":"Gedeon","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.bioorg.2026.110483_bb1030","doi-asserted-by":"crossref","unstructured":"B. Bakchi, S. Maddipatla, S. Gottemukkala, S. Raut, M. Naiyaz Ahmad, M. Imran, D. Saxena, R. Maitra, P. Kumari Agnivesh, N. Pal Kalia, S. Nanduri, A. Dasgupta, S. Chopra, V. Madhavi Yaddanapudi, Benzyl\/phenyl-1,2,3-Triazole tethered 3-acetyl coumarins as potential drug-resistant antitubercular agents: synthesis, biology, and in silico investigations as Mtb DNA gyrase inhibitors, ChemistrySelect 9 (2024) 1\u201315. Doi: https:\/\/doi.org\/10.1002\/slct.202402316.","DOI":"10.1002\/slct.202402316"},{"key":"10.1016\/j.bioorg.2026.110483_bb1035","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1021\/acs.jcim.4c00511","article-title":"Ligand-based virtual screening for discovery of indole derivatives as potent DNA gyrase ATPase inhibitors active against Mycobacterium tuberculosis and hit validation by biological assays","volume":"64","author":"Pakamwong","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.110483_bb1040","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1021\/acs.jmedchem.1c00263","article-title":"Discovery of novel Thiophene-arylamide derivatives as DprE1 inhibitors with potent Antimycobacterial activities","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/1062936X.2021.1900390","article-title":"In silico guided design of non-covalent inhibitors of DprE1: synthesis and biological evaluation","volume":"32","author":"Verma","year":"2021","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.bioorg.2026.110483_bb1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128394","article-title":"Design, synthesis and biological evaluation of novel 6-(trifluoromethyl)-N-(4-oxothiazolidin-3-yl)quinazoline-2-carboxamide derivatives as a potential DprE1 inhibitors","volume":"1217","author":"Gawad","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110483_bb1055","doi-asserted-by":"crossref","first-page":"12790","DOI":"10.1021\/acs.jmedchem.1c00837","article-title":"1,3-Diarylpyrazolyl-acylsulfonamides as potent anti-tuberculosis agents targeting Cell Wall biosynthesis in Mycobacterium tuberculosis","volume":"64","author":"Khonde","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1060","doi-asserted-by":"crossref","unstructured":"W. Xiang, H. He, X. Duan, Z. He, X. Xu, M. Liao, F. Teng, X. Li, T. Luo, J. Zeng, L. Yu, C. Gao, W. Xiang, H. He, X. Duan, Z. He, X. Xu, M. Liao, F. Teng, X. Li, T. Luo, J. Zeng, L. Yu, C. Gao, benzomorpholine for the treatment of tuberculosis, 11 (2023) 1\u201325.","DOI":"10.1128\/spectrum.04721-22"},{"key":"10.1016\/j.bioorg.2026.110483_bb1065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ardp.202000419","article-title":"3-aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents","volume":"354","author":"Karale","year":"2021","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110483_bb1070","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1016\/j.bmcl.2017.05.081","article-title":"Identification and synthesis of novel inhibitors of mycobacterium ATP synthase","volume":"27","author":"Surase","year":"2017","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.110483_bb1075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics11050557","article-title":"Computational Design of Inhibitors Targeting the catalytic \u03b2 subunit of Escherichia coli FO F1-ATP synthase","volume":"11","author":"Avila-Barrientos","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioorg.2026.110483_bb1080","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2174\/1568026620666200903163515","article-title":"ATP synthase inhibitors as anti-tubercular agents: QSAR studies in novel substituted Quinolines","volume":"20","author":"Saxena","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117504","article-title":"Expanding the squaramide library as mycobacterial ATP synthase inhibitors: innovative synthetic pathway and biological evaluation","volume":"95","author":"Chas\u00e1k","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10822-022-00495-w","article-title":"Identification of potential inhibitors of Mycobacterium tuberculosis shikimate kinase: molecular docking, in silico toxicity and in vitro experiments","volume":"37","author":"Freitas de Freitas","year":"2023","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bioorg.2026.110483_bb1095","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1016\/j.jscs.2024.101826","article-title":"Eugenol derivatives containing 1,2,3-triazole-chalcone hybrids for shikimate kinase inhibition","volume":"28","author":"Ardiansah","year":"2024","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110483_bb1100","doi-asserted-by":"crossref","first-page":"21761","DOI":"10.1073\/pnas.1014642108","article-title":"Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis","volume":"107","author":"Kalscheuer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.110483_bb1105","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.bmc.2013.12.058","article-title":"Synthesis of a C-phosphonate mimic of maltose-1-phosphate and inhibition studies on Mycobacterium tuberculosis GlgE","volume":"22","author":"Veleti","year":"2014","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.110483_bb1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0265068","article-title":"Antitubercular activity assessment of fluorinated chalcones, 2-aminopyridine-3- carbonitrile and 2-amino-4H-pyran-3- carbonitrile derivatives: in vitro, molecular docking and in-silico drug likeliness studies","volume":"17","author":"Lagu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110483_bb1115","first-page":"1","article-title":"Sulfonamide derivatives as Mycobacterium tuberculosis inhibitors: in silico approach, in silico","volume":"6","author":"Pradhan","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.bioorg.2026.110483_bb1120","doi-asserted-by":"crossref","first-page":"8452","DOI":"10.1002\/anie.200903821","article-title":"Application of fragment growing and fragment linking to the discovery of inhibitors of mycobacterium tuberculosis pantothenate synthetase","volume":"48","author":"Hung","year":"2009","journal-title":"Angewandte Chemie - International Edition"},{"key":"10.1016\/j.bioorg.2026.110483_bb1125","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1080\/07391102.2023.2291826","article-title":"In vitro and in silico exploration of newly synthesized triazolyl- isonicotinohydrazides as potent antitubercular agents","volume":"43","author":"Bakale","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110483_bb1130","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chembiol.2015.05.016","article-title":"Thiophenecarboxamide derivatives activated by EthA kill Mycobacterium tuberculosis by inhibiting the CTP Synthetase PyrG","volume":"22","author":"Mori","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110483_bb1135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/acsinfecdis.7b00006","article-title":"A phenotypic based target screening approach delivers new Antitubercular CTP Synthetase inhibitors","volume":"3","author":"Esposito","year":"2017","journal-title":"ACS Infectious Diseases"},{"key":"10.1016\/j.bioorg.2026.110483_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/msphere.00369-22","article-title":"A new Benzothiazolthiazolidine derivative, 11726172, is active in vitro, in vivo, and against nonreplicating cells of Mycobacterium tuberculosis","volume":"7","author":"Salina","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.bioorg.2026.110483_bb1145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2019.05.082","article-title":"Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis","volume":"178","author":"Karale","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1150","first-page":"2131","article-title":"Structural insights into Arylidenehydrazinyl Benzenesulfonamides as potent mycobacterial carbonic anhydrase inhibitors, future","volume":"17","author":"Kumar","year":"2025","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110483_bb1155","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500633","article-title":"Exploration of new Pyrazole\u2013Hydrazone\u2013Benzenesulfonamide conjugates as potent mycobacterial carbonic anhydrase inhibitors: design, synthesis, and biological evaluation","volume":"20","author":"Kumar","year":"2025","journal-title":"ChemMedChem"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:23:09Z","timestamp":1791260589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":231,"alternative-id":["S0045206826010199"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110483","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computational small molecule drug discovery for multidrug-resistant tuberculosis: emerging targets and recent medicinal chemistry advances","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110483"}}